Contact Us

The choice depends on the experimental question. SPAG17 is normally expressed in cilia and flagella, particularly in respiratory epithelium and sperm — HEK293 expresses minimal endogenous SPAG17. The Knockout line in HEK293 is most useful for biochemical and interactome studies in a clean background, since HEK293 is not the physiologically relevant cell type for SPAG17 function. Overexpression in HEK293 may be more informative for structural and biochemical characterization of SPAG17. For SPAG17 research focused on physiological function — primary ciliary dyskinesia modeling, sperm motility studies, bone biology (SPAG17 has emerging roles in osteoblast function) — ciliated cell models or primary cells are more appropriate than HEK293. The EDITGENE Knockout in HEK293 is useful for confirming complete loss in cells with low baseline expression and for heterologous expression studies. Rescue with wild-type or epitope-tagged SPAG17 enables initial interactome characterization.

Yes, with important context considerations: • Construct design: SPAG17 is large (~2,223 amino acids); use codon-modified sequences with C-terminal tags (FLAG, HA). Full-length cloning requires careful vector selection. • Heterologous expression context: HEK293 does not normally express SPAG17 at functional levels — rescue is effectively a controlled heterologous expression study. Physiological SPAG17 function in cilia requires ciliated cell models. • Truncation rescue: given SPAG17's size, truncation constructs covering specific domains may be more tractable for biochemical and interactome studies than full-length rescue. • Functional readout: rescue should restore phenotypes identified in discovery transcriptomics or interactome studies; ciliary function readouts are not applicable in HEK293. HEK293 transduces efficiently with lentivirus, though large cargo size may reduce titer; consider multi-vector strategies for full-length SPAG17 delivery.

The choice depends on whether you are studying SLC7A8 (LAT2)'s role as a heterodimeric amino acid transporter or its specific contributions to small neutral amino acid transport in tissues like kidney and small intestine. The Knockout line is the standard tool for asking whether LAT2 is required for system L-like transport of broad-range amino acids — LAT2 partners with 4F2hc/CD98 to form a functional heterodimeric exchanger. Overexpression is useful for transport kinetics studies, but functional surface expression requires 4F2hc coexpression. For amino acid transporter research, the EDITGENE SLC7A8 Knockout in HEK293 is a standard mechanistic platform. Note that LAT2 and LAT1 (SLC7A5) have partially overlapping substrate scopes but distinct affinity profiles — LAT2 has broader substrate range including small neutral amino acids. Rescue with wild-type or transport-deficient LAT2 enables structure-function dissection.

Yes. LAT2 rescue experiments require attention to heterodimer partnership requirements: • Construct design: use a codon-modified SLC7A8 sequence with a small C-terminal tag (FLAG, HA). LAT2 has 12 transmembrane domains — N-terminal tags must not disrupt membrane topology. • 4F2hc co-expression: LAT2 requires 4F2hc/CD98/SLC3A2 for functional surface expression — rescue cells should be characterized for 4F2hc expression, or co-rescue with 4F2hc may be needed in 4F2hc-low backgrounds. • Transport-deficient rescue: substrate-binding pocket mutations enable distinguishing transport activity from non-transport functions. • Functional readout: rescue should restore small/medium neutral amino acid uptake measured by radiolabel or LC-MS detection. HEK293 transduces efficiently with lentivirus and supports the bicistronic or co-rescue strategies often needed for heterodimeric transporter studies.

The choice depends on whether you are studying SLC46A3's role as a lysosomal transporter critical for antibody-drug conjugate (ADC) efficacy or its emerging endogenous functions as a proton-coupled steroid conjugate and bile acid transporter. The Knockout line is the standard tool for asking whether SLC46A3 is required for releasing noncleavable ADC catabolites from the lysosome to the cytoplasm — SLC46A3 directly transports Lys-SMCC-DM1 (the major catabolite of trastuzumab emtansine/T-DM1) and is a critical determinant of T-DM1 efficacy. Overexpression is useful for studying mechanisms of restoring ADC sensitivity in resistant cells. For ADC research, the EDITGENE SLC46A3 Knockout in HEK293 is a highly relevant mechanistic platform — SLC46A3 loss is a defined mechanism of innate and acquired resistance to maytansine-based (DM1) and pyrrolobenzodiazepine (PBD/SG3376) noncleavable ADCs, with patient relevance as a predictive biomarker. Rescue with wild-type SLC46A3 restores ADC sensitivity in resistant lines — this rescue paradigm is established in the literature. Rescue with transport-deficient variants enables structure-function studies.

Yes. SLC46A3 rescue experiments are well-established in ADC research: • Construct design: use a codon-modified SLC46A3 sequence with a small C-terminal tag (FLAG, HA). SLC46A3 is a lysosomal membrane protein — small tags and proper lysosomal targeting signals must be preserved. • Lysosomal localization validation: confirm lysosomal localization of exogenous SLC46A3 by LAMP1 co-staining before ADC sensitivity assays. • Transport-deficient rescue: substrate-binding mutations enable distinguishing ADC catabolite transport from non-transport functions. • Functional readout: rescue should restore T-DM1 cytotoxicity — sensitivity restoration in resistant lines is the established positive control. Lysosomal Lys-SMCC-DM1 retention by mass spectrometry confirms transport function rescue. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for ADC sensitivity studies.

The choice depends on whether you are studying SLC2A13 (HMIT)'s role as a H⁺-coupled myo-inositol transporter or its emerging functions in neuronal inositol signaling and APP processing in Alzheimer's disease contexts. The Knockout line is the standard tool for asking whether SLC2A13 is required for proton-coupled myo-inositol uptake — HMIT is unique among GLUT family members in transporting inositol rather than hexoses, and unique in coupling transport to a proton gradient rather than facilitative diffusion. Overexpression is useful for testing transport activity in heterologous systems or for studying HMIT's reported role as a binding partner of presenilin and modulator of γ-secretase activity. For HMIT research, the EDITGENE SLC2A13 Knockout in HEK293 is a standard mechanistic platform — HEK293 has been extensively used for HMIT biochemistry and APP/γ-secretase signaling research. Rescue with wild-type or transport-deficient HMIT enables structure-function studies, and is particularly valuable for distinguishing transport function from HMIT's reported scaffolding roles in APP processing.

Yes. HMIT rescue experiments require attention to proton coupling and pH dependence: • Construct design: use a codon-modified SLC2A13 sequence with a small C-terminal tag (FLAG, HA). HMIT has 12 transmembrane domains — N-terminal tags must not disrupt topology. • Transport-deficient rescue: conserved residue mutations in the H⁺ or myo-inositol binding pockets enable structure-function studies — including the conserved aspartate residues critical for proton coupling. • pH-dependence: HMIT transport is highly pH-sensitive, with optimal activity in acidic conditions (pH 5.0-6.0) — rescue assays should be performed under controlled pH conditions. • Functional readout: rescue should restore proton-coupled myo-inositol uptake and, where relevant, modulation of γ-secretase activity on APP substrates. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for HMIT functional studies.

The choice depends on whether you are studying SLC30A1 (ZnT1)'s role as the principal plasma membrane zinc efflux transporter or its functions in cellular zinc homeostasis. The Knockout line is the standard tool for asking whether ZnT1 is required for cellular zinc export — ZnT1 is the major zinc extrusion transporter in most cell types and is essential for preventing intracellular zinc overload. Overexpression is useful for testing whether elevated ZnT1 enhances zinc efflux or for studying cancer-associated ZnT1 regulation. For zinc homeostasis research, the EDITGENE SLC30A1 Knockout in HEK293 enables study of cellular zinc efflux and tolerance to zinc challenge. Note that complete ZnT1 loss may sensitize cells to zinc toxicity — characterize zinc tolerance phenotypes before extended use. Rescue with wild-type or transport-deficient ZnT1 enables structure-function studies.

Yes. ZnT1 rescue experiments require attention to plasma membrane targeting: • Construct design: use a codon-modified SLC30A1 sequence with a small C-terminal tag (FLAG, HA). The 6 transmembrane ZnT family architecture must be preserved. • Transport-deficient rescue: histidine-rich loop mutations or transmembrane zinc-binding site mutations enable structure-function studies. • Surface localization validation: confirm plasma membrane localization by cell surface staining before zinc efflux assays. • Functional readout: rescue should restore cellular zinc efflux and zinc tolerance under challenge conditions. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ferroportin's role as the principal cellular iron exporter or modeling hemochromatosis type 4 and ferroportin disease. The Knockout line is the standard tool for asking whether ferroportin is required for iron efflux — ferroportin is the only known mammalian cellular iron export transporter, expressed on enterocytes, macrophages, and hepatocytes. Overexpression is useful for studying ferroportin in heterologous expression systems and for testing hepcidin-mediated regulation. For iron homeostasis research, the EDITGENE Ferroportin Knockout in HEK293 is the standard mechanistic platform — HEK293 has been extensively used for ferroportin biochemistry and structural studies. Rescue with wild-type, hepcidin-resistant (C326S), or ferroportin disease-associated mutant SLC40A1 enables comprehensive disease modeling. SLC40A1 mutations cause autosomal dominant hemochromatosis type 4/ferroportin disease — disease variant rescue is a standard genotype-function approach.

Yes. Ferroportin rescue experiments are well-established in iron biology research: • Construct design: use a codon-modified SLC40A1 sequence with a small C-terminal tag (FLAG, HA). Ferroportin has 12 transmembrane domains — N-terminal tags must not disrupt topology. • Hepcidin-resistant rescue: the C326S mutation prevents hepcidin binding and creates a hepcidin-insensitive ferroportin — invaluable for studying iron export independent of hepcidin regulation. • Disease mutation rescue: A77D (classical 'loss-of-function'), N144H, and other hemochromatosis type 4-associated mutations enable disease genotype-function studies. • Functional readout: rescue should restore ⁵⁹Fe efflux from preloaded cells and hepcidin-induced ferroportin internalization (where wild-type protein is used). HEK293 transduces efficiently with lentivirus and is the standard heterologous expression background for ferroportin biochemistry and disease modeling.

The choice depends on whether you are studying SLC37A4 (glucose-6-phosphate translocase/G6PT)'s role in hepatic and renal glucose-6-phosphate transport or modeling glycogen storage disease type Ib. The Knockout line is the standard tool for asking whether G6PT is required for transporting glucose-6-phosphate across the ER membrane — G6PT partners with glucose-6-phosphatase to enable gluconeogenesis and glycogenolysis. Overexpression is useful for testing rescue with disease-associated mutations or for biochemical reconstitution studies. For glucose metabolism research, the EDITGENE SLC37A4 Knockout in HEK293 is a mechanistic platform, though physiological gluconeogenesis requires hepatic models. SLC37A4 mutations cause glycogen storage disease type Ib (GSD1b), characterized by hypoglycemia, neutropenia, and inflammatory bowel disease — disease variant rescue enables genotype-function studies. Empagliflozin has been shown to treat GSD1b neutropenia, making this knockout relevant for SGLT2 inhibitor mechanism studies in this context.

Yes. G6PT rescue experiments are well-established for GSD1b research: • Construct design: use a codon-modified SLC37A4 sequence with a small cytoplasmic C-terminal tag (FLAG, HA). G6PT is an ER membrane protein with 10 transmembrane domains — preserve ER targeting determinants. • ER localization validation: confirm ER localization by calnexin co-staining before functional assays. • GSD1b mutation rescue: patient-derived SLC37A4 mutations (e.g., R28H, W118R, common deletions) enable comprehensive disease genotype-function studies. • Functional readout: rescue should restore glucose-6-phosphate translocation activity measured in microsomal preparations. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC30A3 (ZnT3)'s role in vesicular zinc loading or its functions in synaptic zinc and Alzheimer's disease contexts. The Knockout line is the standard tool for asking whether ZnT3 is required for transporting zinc into synaptic vesicles — ZnT3 is principally expressed in zincergic neurons in the hippocampus and cortex. Overexpression is useful for studying vesicular zinc loading in heterologous systems. Important consideration: ZnT3 is primarily neuronal — HEK293 is not the physiological context for ZnT3 function. The EDITGENE Knockout in HEK293 is most useful for in vitro biochemistry, structure-function studies, and as a negative control background for heterologous ZnT3 reconstitution. For physiological synaptic zinc research, neuronal models are more appropriate. Rescue with wild-type or transport-deficient ZnT3 enables mechanistic dissection.